Redhill Biopharma Ltd Asset Resilience Ratio
Redhill Biopharma Ltd asset resilience ratio. Redhill Biopharma Ltd (RDHL) has an Asset Resilience Ratio of 10.35% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See RDHL defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Redhill Biopharma Ltd (2010–2024)
Asset resilience ratio of Redhill Biopharma Ltd from 2010 to 2024. This chart shows how Redhill Biopharma Ltd's Asset Resilience Ratio has changed over time. Read Redhill Biopharma Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Redhill Biopharma Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see RDHL asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.62 Million | 10.35% |
| Total Liquid Assets | $2.62 Million | 10.35% |
Asset Resilience Insights
- Moderate Liquidity: Redhill Biopharma Ltd has 10.35% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Redhill Biopharma Ltd Industry Peers by Asset Resilience Ratio
Compare Redhill Biopharma Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Redhill Biopharma Ltd Asset Resilience Ratio by Year (2010–2024)
Redhill Biopharma Ltd asset resilience ratio by year from 2010 to 2024. The table below shows the annual Asset Resilience Ratio data for Redhill Biopharma Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.16% | $2.73 Million | $18.04 Million | +11.73pp |
| 2023-12-31 | 3.43% | $790.04K | $23.05 Million | +3.42pp |
| 2022-12-31 | 0.01% | $15.00K | $158.87 Million | -4.70pp |
| 2021-12-31 | 4.71% | $8.53 Million | $181.19 Million | +4.43pp |
| 2020-12-31 | 0.28% | $498.00K | $180.24 Million | -25.16pp |
| 2019-12-31 | 25.44% | $18.85 Million | $74.10 Million | -13.31pp |
| 2018-12-31 | 38.74% | $24.18 Million | $62.41 Million | -13.14pp |
| 2017-12-31 | 51.88% | $29.75 Million | $57.34 Million | +35.22pp |
| 2016-12-31 | 16.67% | $12.37 Million | $74.21 Million | -38.13pp |
| 2015-12-31 | 54.80% | $36.62 Million | $66.83 Million | -4.30pp |
| 2014-12-31 | 59.10% | $17.05 Million | $28.86 Million | +57.27pp |
| 2013-12-31 | 1.83% | $262.00K | $14.34 Million | -5.89pp |
| 2012-12-31 | 7.72% | $1.55 Million | $20.10 Million | -14.96pp |
| 2011-12-31 | 22.67% | $4.58 Million | $20.19 Million | +22.53pp |
| 2010-12-31 | 0.14% | $15.00K | $10.51 Million | -- |
About Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for … Read more